Risk of venous thromboembolism among women receiving ospemifene: a comparative observational study
Introduction: The primary aim of this study was to compare the incidence of venous thromboembolism (VTE) among women initiating ospemifene vs other selective estrogen receptor modulator (SERM) therapies for estrogen-deficiency conditions or breast cancer prevention, and vs women with untreated vulva...
Main Authors: | Beth L. Nordstrom, Bin Cai, Fabio De Gregorio, Lu Ban, Kathy H. Fraeman, Yuki Yoshida, Trevor Gibbs |
---|---|
Format: | Article |
Language: | English |
Published: |
SAGE Publishing
2022-11-01
|
Series: | Therapeutic Advances in Drug Safety |
Online Access: | https://doi.org/10.1177/20420986221135931 |
Similar Items
-
Ospemifene for vulvar and vaginal atrophy: an overview
by: Santiago Palacios
Published: (2020-07-01) -
Safety and efficacy of ospemifene for the treatment of dyspareunia associated with vulvar and vaginal atrophy due to menopause
by: Wurz GT, et al.
Published: (2014-11-01) -
Ospemifene for the treatment of dyspareunia associated with vulvar and vaginal atrophy: potential benefits in bone and breast
by: Soe LH, et al.
Published: (2013-09-01) -
Venous anomalies and thromboembolism
by: Caroline Dix, et al.
Published: (2023-04-01) -
Ospemifene May Not Treat Vulvar Atrophy: A Report of Two Cases
by: Andrew T. Goldstein, MD, et al.
Published: (2016-09-01)